Phathom Pharmaceuticals (PHAT) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Phathom Pharmaceuticals (PHAT) has outperformed Rezolute (RZLT) over the past year, losing 35.5% versus a loss of 46.8%. Over five years, RZLT leads with a -30.2% price change compared with -78.1% for PHAT. Phathom Pharmaceuticals is the larger company by market cap ($576.8 million vs $448.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHAT | RZLT |
|---|---|---|
| Share price | $7.13 | $4.64 |
| Market cap | $576.82M | $448.79M |
| 1-day change | +4.70% | +5.94% |
| YTD return | -57.02% | +96.61% |
| 1-year return | -35.48% | -46.79% |
| 5-year return | -78.07% | -30.23% |
| Forward P/E | 6.62 | — |
| EPS (TTM) | $-1.26 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.31 | $11.46 |
| 52-week low | $6.52 | $1.07 |
| Distance from 52-week high | -61.06% | -59.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +186.82% | +111.21% |
| Average volume | 1.38M | 1.50M |
| Shares outstanding | 80.90M | 96.72M |
| Employees | 371 | 58 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHAT has outperformed RZLT by 11.3 percentage points over the past year.
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Healthcare · Biotechnology · 371 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Healthcare · Biotechnology · 58 employees
PHAT vs RZLT FAQ
Which is bigger, Phathom Pharmaceuticals or Rezolute?
Phathom Pharmaceuticals (PHAT) is larger, with a market capitalization of $576.82M compared with $448.79M for Rezolute (RZLT).
Which stock has performed better over the past year, PHAT or RZLT?
PHAT returned -35.48% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Phathom Pharmaceuticals and Rezolute in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.